Article thumbnail

BPR1K653, a Novel Aurora Kinase Inhibitor, Exhibits Potent Anti-Proliferative Activity in MDR1 (P-gp170)-Mediated Multidrug-Resistant Cancer Cells

By Chun Hei Antonio Cheung, Wen-Hsing Lin, John Tsu-An Hsu, Tzyh-Chyuan Hour, Teng-Kuang Yeh, Shengkai Ko, Tzu-Wen Lien, Mohane Selvaraj Coumar, Jin-Fen Liu, Wen-Yang Lai, Hui-Yi Shiao, Tian-Ren Lee, Hsing-Pang Hsieh and Jang-Yang Chang
Topics: Research Article
Publisher: Public Library of Science
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2006). 1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: identification of a potent Aurora kinase inhibitor with a favorable antitumor kinase inhibition profile.
  2. (2007). A novel oral indolinesulfonamide agent, N-[1-(4-methoxybenzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-isonicotinamide (J30), exhibits potent activity against human cancer cells in vitro and in vivo through the disruption of microtubule.
  3. (2009). Advances in Aurora kinase inhibitor patents.
  4. (2010). Antineoplastic effects of an Aurora B kinase inhibitor in breast cancer.
  5. (2007). Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase.
  6. (2008). Aurora A is essential for early embryonic development and tumor suppression.
  7. (2007). Aurora B expression correlates with aggressive behaviour in glioblastoma multiforme.
  8. (2006). Aurora kinase A messenger RNA overexpression is correlated with tumor progression BPR1K653, a Novel Pan-Aurora Kinase Inhibitor
  9. (2010). Aurora kinase inhibitor patents and agents in clinical testing: an update (2009–10) This article is an update to aurora kinase inhibitors review, which appeared in:
  10. (2009). Aurora kinase inhibitors in preclinical and clinical testing.
  11. (2004). Autophosphorylation of a Newly Identified Site of Aurora-B Is Indispensable for Cytokinesis.
  12. (2007). AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis.
  13. (2009). Biochemical characterization of GSK1070916, a potent and selective inhibitor of Aurora B and Aurora C kinases with an extremely long residence time1.
  14. (2004). BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo.
  15. (2010). Chamaecypanone C, a novel skeleton microtubule inhibitor, with anticancer activity by trigger caspase 8-Fas/FasL dependent apoptotic pathway in human cancer cells.
  16. (2010). Cisplatin sensitivity of testis tumour cells is due to deficiency in interstrandcrosslink repair and low ERCC1-XPF expression.
  17. (1988). Combined modalities of resistance in etoposide-resistant human KB cell lines.
  18. (2007). Constitutive phosphorylation of aurora-a on ser51 induces its stabilization and consequent overexpression in cancer.
  19. (1998). Decreased drug accumulation without increased drug efflux in a novel MRP-overexpressing multidrug-resistant cell line.
  20. (2010). Down-regulation of the Nucleotide Excision Repair gene XPG as a new mechanism of drug resistance in human and murine cancer cells.
  21. (1990). Expression of the multidrug resistance, MDR1, gene in neuroblastomas.
  22. (2006). Frequent overexpression of aurora B kinase, a novel drug target, in non-small cell lung carcinoma patients.
  23. (2008). Frequent overexpression of Aurora Kinase A in upper gastrointestinal adenocarcinomas correlates with potent antiapoptotic functions.
  24. (2010). Glucosylceramide synthase upregulates MDR1 expression in the regulation of cancer drug resistance through cSrc and beta-catenin signaling.
  25. (2009). GSK1070916, a potent Aurora B/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft models.
  26. (1995). Human myeloma cell lines as a tool for studying the biology of multiple myeloma: a reappraisal 18 years after [letter].
  27. (2009). Identification of genes that confer tumor cell resistance to the aurora B kinase inhibitor, AZD1152.
  28. (2010). Identification, SAR studies, and X-ray co-crystallographic analysis of a novel furanopyrimidine aurora kinase A inhibitor.
  29. (2010). Inhibition of ABCB1 (MDR1) expression by an siRNA nanoparticulate delivery system to overcome drug resistance in osteosarcoma.
  30. (2007). Inhibition of Aurora-B function increases formation of multinucleated cells in p53 gene deficient cells and enhances anti-tumor effect of temozolomide in human glioma cells.
  31. (2001). Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines.
  32. (1994). MDR1 gene expression: its effect on drug resistance to doxorubicin in human hepatocellular carcinoma cell lines.
  33. (2003). MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models.
  34. (1989). MDR1 RNA levels in human renal cell carcinomas: correlation with grade and prediction of reversal of doxorubicin resistance by quinidine in tumor explants.
  35. (2007). MLN8054, a small-molecule inhibitor of Aurora A, causes spindle pole and chromosome congression defects leading to aneuploidy.
  36. (2005). Overexpression of aurora B kinase (AURKB) in primary non-small cell lung carcinoma is frequent, generally driven from one allele, and correlates with the level of genetic instability.
  37. (2003). P-glycoprotein modulation improves in vitro chemosensitivity in malignant pediatric liver tumors.
  38. (2007). PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer.
  39. (2006). Phospho-regulation of human protein kinase Aurora-A: analysis using antiphospho-Thr288 monoclonal antibodies.
  40. (2010). Preclinical Evaluation of AMG 900, a Novel Potent and Highly Selective Pan-Aurora Kinase Inhibitor with Activity in Taxane-Resistant Tumor Cell Lines.
  41. (2002). Probing the dynamics and functions of aurora B kinase in living cells during mitosis and cytokinesis.
  42. (2010). SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo.
  43. (2009). Survivin counteracts the therapeutic effect of microtubule de-stabilizers by stabilizing tubulin polymers.
  44. (2006). The Aurora kinase inhibitor VX-680 induces endoreduplication and apoptosis preferentially in cells with compromised p53-dependent postmitotic checkpoint function.
  45. (1999). The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review.
  46. (2004). The synergistic cytotoxicity of cisplatin and taxol in killing oral squamous cell carcinoma.
  47. (1989). Two epithelial tumor cell lines (HNE-1 and HONE-1) latently infected with Epstein-Barr virus that were derived from nasopharyngeal carcinomas.
  48. (2007). VX-680 inhibits Aurora A and Aurora B kinase activity in human cells.
  49. (2004). VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo.